ArticleDiabetology & metabolic syndrome2026
Screening performance of the FINDRISC score for identification of undiagnosed type 2 diabetes in persons with severe obesity.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundType 2 diabetes mellitus (T2DM) and prediabetes are common complications of severe obesity. Although the Finnish Diabetes Risk Score (FINDRISC) is a widely used tool for diabetes risk assessment, its performance has not been specifically evaluated in populations with severe obesity.
methodsIn this cross-sectional study, 632 adults with severe obesity (median BMI 46.2 kg/m²) underwent oral glucose tolerance testing (OGTT) and HbA1c assessment. FINDRISC was calculated for each participant. The primary endpoint was the ability of FINDRISC to identify previously undiagnosed T2DM. Secondary endpoints included the prevalence of glycemic categories and the associations between FINDRISC and circulating adipokines.
resultsNormoglycemia, prediabetes, and previously undiagnosed T2DM were identified in 44%, 46%, and 10% of participants, respectively. FINDRISC values increased progressively with worsening glucose tolerance (p < 0.001). The area under the ROC curve for detection of undiagnosed T2DM was 0.72 (95% CI 0.65-0.78). A FINDRISC cut-off of 13 showed high sensitivity (95.1%) and negative predictive value (98.2%), allowing 26% of individuals to be spared additional blood testing. Adiponectin and leptin levels were significantly lower in participants with diabetes compared with those with normoglycemia or prediabetes.
conclusionsApproximately one in ten persons with severe obesity had previously undiagnosed T2DM. In this population, FINDRISC demonstrated good performance as a rule-out screening tool, supporting its use to reduce unnecessary diagnostic testing and to guide targeted diabetes screening in severe obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.